- Home
- SGLY vs SCNX Comparison
SGLY vs SCNX Comparison
Compare SGLY & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- SCNX
- Stock Information
- Founded
- SGLY 2001
- SCNX 2010
- Country
- SGLY United States
- SCNX United States
- Employees
- SGLY N/A
- SCNX N/A
- Industry
- SGLY
- SCNX Other Pharmaceuticals
- Sector
- SGLY
- SCNX Health Care
- Exchange
- SGLY Nasdaq
- SCNX Nasdaq
- Market Cap
- SGLY 5.8M
- SCNX 59.2M
- IPO Year
- SGLY 2008
- SCNX 2020
- Fundamental
- Price
- SGLY $1.55
- SCNX $7.58
- Analyst Decision
- SGLY
- SCNX
- Analyst Count
- SGLY 0
- SCNX 0
- Target Price
- SGLY N/A
- SCNX N/A
- AVG Volume (30 Days)
- SGLY 14.2K
- SCNX 13.8K
- Earning Date
- SGLY 11-14-2024
- SCNX 02-10-2025
- Dividend Yield
- SGLY N/A
- SCNX N/A
- EPS Growth
- SGLY N/A
- SCNX N/A
- EPS
- SGLY N/A
- SCNX 3.55
- Revenue
- SGLY $2,742,157.00
- SCNX N/A
- Revenue This Year
- SGLY N/A
- SCNX $1,085.75
- Revenue Next Year
- SGLY N/A
- SCNX N/A
- P/E Ratio
- SGLY N/A
- SCNX $3.23
- Revenue Growth
- SGLY N/A
- SCNX 166.67
- 52 Week Low
- SGLY $1.27
- SCNX $3.69
- 52 Week High
- SGLY $7.65
- SCNX $44.56
- Technical
- Relative Strength Index (RSI)
- SGLY 43.10
- SCNX N/A
- Support Level
- SGLY $1.58
- SCNX N/A
- Resistance Level
- SGLY $1.71
- SCNX N/A
- Average True Range (ATR)
- SGLY 0.09
- SCNX 0.00
- MACD
- SGLY -0.00
- SCNX 0.00
- Stochastic Oscillator
- SGLY 35.71
- SCNX 0.00
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.